SpecimenSeq™ FFPE & Plasma

SpecimenSEQ™
Matched FFPE & Plasma

The SpecimenSeq™ FPPE inventory report contains:

  • 592 detections of 60 specific genes across 15 oncology indications and 99 unique patients. Each FFPE & Plasma set is fully consented and ethically collected from treatment naive cancer patients.
 

Inventory Request Submission:

  1. Download and review the inventory report.
  2. Highlight your samples of interest and save the report.
  3. Submit the saved inventory report file via the contact form linked below, along with any additional details or requests.

Conduct smarter oncology R&D faster with SpecimenSEQ™

Overview:

Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for targeted oncology and liquid biopsy developers by delivering access to ethically collected biospecimen sets that are comprehensively annotated by genomic and clinical characteristics.

Image

SpecimenSeq™

Deliverables &
Characterization

Matched FFPE & Plasma

Matched Biospecimen Sets, Same Donor Across
Different Sample Formats

Biospecimen FormatQuantityCharacterization reports
FFPE1• Clinical information and pathology report
• HAD QGEN MultiModal service with Qiagen Clinical Insights (QCI) report
Double Spun plasma4 mL• Clinical information and pathology report
Buffy coat (Optional)-0.3 mL• Clinical information and pathology report

NGS Characterization

DNA Gene Content (64 Genes)
ABL1CDH1ERFLT3IDH2MLH1PDGFRASMAD4
AKT1CDKN2AERBB2FOXL2JAK2MPLPIK3CASMARCB1
ALKCSF1RERBB4GNA11JAK3MSH2PMS2SMO
APCCTLA4EZH2GNAQKDRMSH6PRSRC
ATMCTNNB1FBXW7GNASKITMUM1PTENSTK11
BCL6DDR2FGFR1HNF1AKRASNOTCH1PTPN11TP53
BRAFDNMT3AFGFR2HRASMAP2K1NPM1RB1TSC1
CD10EGFRFGFR3IDH1METNRASRETVHL
RNA GENE FUSION CONTENT (6 PRIMARY GENES)
EML4-ALKMPRIP-NTRK1NCOA4-RET
GCC2-ALKSQSTM1-NTRK1TRIM33-RET
HIP1-ALKTPR-NTRK1CD74-ROS1
KIF5B-ALKTRIM24-NTRK2EZR-ROS1
KLC1-ALKETV6-NTRK3GOPC-RPS1
STRN-ALKSQSTM1-NTRK3LRIG3-ROS1
TFG-ALKCCDC6-RETSDC4-ROS1
TPR-ALKCUX1-RETSLC34A2-ROS1
CD74-NTRK1KIAA1217-RETTPM3-ROS1
IRF2BP2-NTRK1KIF5B-RET 

NGS results are delivered via a Qiagen Clinical Insights (QCI) report that includes:

  • Genomic variants that have been shown to have clinical relevance
  • Pathogenicity and level of clinical significance according to clinical guidelines
  • Predicted protein changes
  • Relevant drug treatments or resistance to drugs based on the genetic variants
  • Relevant active clinical trials for patients that would harbor the same genomic variants as were identified in the biospecimen sample

Additional characteristics are available through our expert, integrated service laboratories.

Image

IHC Services

Image

Cell Services

Applications:

Image

Liquid
Biopsy

Development and validation of novel liquid biopsy diagnostic solutions

Image

Biomarker
Discovery

Verification of the presence of biomarker targets in your populations of interest

Image

Assessing
Mutations

Confirmation of driver mutations and other clinically relevant genomic variants across FFPE samples

Image

Oncology
Therapeutics

Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies

To propel your projects with The Power of Discovery.™

Contact Us Today

Let us know about your project!

Image